Company
Genetic Signatures Limited
Headquarters: Sydney, NSW, Australia
CEO: Dr. John R. Melki BSc, Ph.D.
Market Cap
A$69.3 Million
AUD as of Jan. 1, 2024
US$47.2 Million
Genetic Signatures Limited Categories
Australia Healthcare Diagnostics & ResearchAustralia Healthcare Australia Diagnostics & Research
Top Competitors by Market Capitalization
Industry: Diagnostics & Research
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $207.62 B |
| Danaher | $171.89 B |
| Siemens Healthineers AG | $66.05 B |
| DexCom, Inc. | $46.50 B |
| IDEXX Laboratories, Inc. | $44.72 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, Asia Pacific, North America, Europe, the Middle East, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious diseases under EasyScreen brand name. The company also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens. In addition, it offers detection kits for gastrointestinal infections, respiratory pathogens, sexual health, anti-microbial resistance, meningitis, and tropical disease. The company was incorporated in 2001 and is headquartered in Newtown, Australia.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Genetic Signatures Limited has the following listings and related stock indices.
Stock: ASX: GSS wb_incandescent